Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current perspectives on FTY720.

Sebastian Martini1, Harm Peters, Torsten Böhler

  • 1Charité, Universitätsmedizin Berlin, Department of Nephrology, Berlin, Germany. Sebastian.Martini@charite.de

Expert Opinion on Investigational Drugs
|March 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Confronted with the real world: how final-year medical students experience interprofessional collaboration in clinical practice.

BMC medical education·2026
Same author

Unheard Voices from Earth: A Fable from 2184.

Medical education·2025
Same author

[Organize teaching in the surgical rotation -What practical experience do students starting the final year clerkship have?]

Chirurgie (Heidelberg, Germany)·2025
Same author

From professional tasks to contexts: A consensus study on chief complaints as clinical anchors for EPAs for entry into residency.

Medical teacher·2025
Same author

ASPIRE-to-excellence: A framework for developing innovative and inspirational approaches to health professions education.

Medical teacher·2025
Same author

Mapping the undergraduate medical curriculum of the Charité Berlin against the National Competence-Based Catalogue of Learning Objectives (NKLM 2.0).

GMS journal for medical education·2025

New oral immunosuppressant FTY720 (fingolimod) shows promise for transplantation and autoimmune diseases. Its novel sphingosine-1 receptor modulation mechanism offers potential with fewer side effects, supported by recent clinical trial results.

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • The need for effective immunosuppressants with improved safety profiles is critical for organ transplantation and managing autoimmune diseases.
  • Sphingosine-1 receptor modulation represents a novel therapeutic strategy to address these unmet clinical needs.

Purpose of the Study:

  • To review the preclinical and clinical findings of FTY720 (fingolimod), an oral sphingosine-1 receptor modulator.
  • To discuss the implications of recent Phase III transplantation and Phase II multiple sclerosis studies for future therapeutic applications.

Main Methods:

  • Review of preclinical data in transplantation and autoimmune disease models.
  • Analysis of pharmacokinetic and pharmacodynamic data from Phase I studies.
  • Evaluation of recently published Phase III de novo renal transplant studies and a Phase II relapsing multiple sclerosis study.

Related Experiment Videos

Main Results:

  • Preclinical studies demonstrated promising efficacy of FTY720 in relevant disease models.
  • Phase I studies established the pharmacokinetic and pharmacodynamic profile of FTY720.
  • Recent Phase III and Phase II studies reported significant clinical outcomes in renal transplant and multiple sclerosis patients, respectively.

Conclusions:

  • FTY720 (fingolimod) exhibits potential as an effective oral immunosuppressant with a novel mechanism of action.
  • The findings support the continued investigation and potential clinical use of sphingosine-1 receptor modulation in transplantation and autoimmune disorders.